Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.

Also called NCT02301910

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 382 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02301910
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02301910. Randomized; no masking; primary purpose treatment. Start 2014-05-16 (actual); primary completion 2016-12-01 (actual). Results posted on 2025-03-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
Acronym
FRIDOM1
Intervention (Drug)
Recombinant staphylokinase
Intervention (Drug)
Tenecteplase
Lead sponsor
Supergene, LLC (class: industry)

Record details

Record id
cardio:ct-nct02301910
Content hash
7a419d06d566b97fbfe6e6ec7c89d9bcb31b999ca7b1d34f0022f9a3b582df35